With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. [SAN ANTONIO, TX – November 5, 2025] NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, Japan. Under the guidance of Dr. Toshio Shimizu as the Director of the Phase I …
Future-Ready Trials: Uniting Sites and CROs Through Technology Adoption to Advance Research
Authors: Marnie Sanders, Vice President, proXimity™, Equicare Health, Inc. Melanie Morris, Associate Director, Precision Site Network, Precision for Medicine Maureen Thompson, Chief Technology Officer, NEXT Oncology This white paper, co-authored by representatives from NEXT Oncology, Precision for Medicine, and Equicare Health, serves as both a case study and a call to action: the future of clinical trials depends on collaboration, technology adoption, …
NEXT Oncology’s Ildefonso Ismael Rodriguez Rivera, MD Leads Phase 1 Trial of Precemtabart-Tocentecan in Metastatic Colorectal Cancer
Phase 1 trial findings published in Nature Medicine show promise for a new approach to targeting colorectal cancer and other tumors expressing CEACAM5. NEXT Oncology’s Dr. Ildefonso Ismael Rodriguez Rivera, a medical oncologist and hematologist in the San Antonio office, has led an innovative Phase 1 clinical trial of precemtabart tocentecan (Precem-TcT) focused on metastatic colorectal cancer, with results now …
NEXT Oncology Expands to Brazil in Strategic Partnership with Oncologia D’Or and IDOR
With continued global expansion, NEXT Oncology is one of the world’s largest Phase 1 Cancer Trial organizations. (SAN ANTONIO, TX) July 29, 2025 –– NEXT Oncology has expanded its services to Brazil through a strategic partnership with Onco D’Or Oncologia S.A., the subsidiary of Rede D’Or São Luiz (RDOR3) for oncology services, and IDOR – Instituto D’Or de Pesquisa e …
Dr. David Sommerhalder Named 2025 San Antonio Business Journal Health Care Hero
We are so proud that Dr. David Sommerhalder has been selected as a 2025 Health Care Hero in the Medical Research Category by the San Antonio Business Journal. Read more here (subscription required)
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations. Read More
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment. Read More
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, in patients with advanced solid tumors. Read More
NEXT Oncology Names Dr. Alex Spira Chief Scientific Officer
Dr. Spira to lead scientific and research strategy, advancing Phase 1 oncology trials. SAN ANTONIO, TX – May 20, 2025 – NEXT Oncology, one of the world’s largest Phase 1 cancer clinical trial centers, has appointed Alex Spira, MD, PhD, FACP, its new Chief Scientific Officer. Dr. Spira, who currently leads NEXT Oncology – Virginia, will now oversee the company’s …
Crown Bioscience and NEXT Oncology Cement Partnership Extension
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks. Read More